CoronaryAtlas logo
CoronaryAtlas
Fibroblast Growth Factor 23
Pathway / Off-pathway / systemic markers

Fibroblast Growth Factor 23

FGF23protein

FGF23 acts as a systemic prognostic biomarker for acute coronary syndrome severity and post-MI mortality, reflecting hemodynamic and metabolic stress.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationalePrognostic marker in ACS; renal/systemic axis off-pathway.
Also acts inCap degradation / rupture
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000118972

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
43
C — confounder / Type-II
86
A — assay feasibility
72
E — evidence strength
32
T1DI (composite)
7
Specificity differential (R−C)-42.4
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(7)

Clinical trials(1)